Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe alcohol use disorder showed a reduction in heavy drinking days and drinks per ...

Study: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder A Randomized Clinical Trial. Image Credit: simon jhuan/Shutterstock.com A recent JAMA Psychiatry study investigates the effectiveness ...

An experimental study of individuals with moderate to severe alcohol use disorder found that semaglutide did not reduce a primary laboratory measure of alcohol craving or drinks per day compared to ...

A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder AURORA, Colo., ...

Newswise — The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research led by ...

The first published evidence from humans that semaglutide specifically reduces the symptoms of alcohol use disorder (AUD) has been published in The Journal of Clinical Psychiatry and details a recent ...

A once-weekly injection of semaglutide could cut alcohol cravings and reduce the amount someone living with alcohol use disorder (AUD) drinks on some days in a given week, according to results from a ...

People with alcohol use disorder who took semaglutide, also known as Wegovy, drank less and had fewer cravings for alcohol, new research found. Reading time 3 minutes A study out this week suggests ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further clinical ...

A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and ...

AURORA, Colo., July 29, 2026 /PRNewswire/ -- A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy ...